SNY News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

SN

Mkt Cap

$97.31B

Volume

3.87M

Next Earnings

October 30th

Chart Financials Earnings News About Dividends Insider Filings

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?Nektar Therapeutics (NKTR) initiated two Phase III studies (ZENITH AD-1 and ZENITH AD-2) for rezpeg in atopic dermatitis in July 2026, with top-line data expected mid-2028. The company plans Phase III studies for alopecia areata in early 2027 and expects Type I diabetes data in 2027. Rezpeg, a self-administered injection that activates regulatory T-cells, faces competition from established players like Sanofi/Regeneron's Dupixent. NKTR trades at a valuation discount to the industry with a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Oct 15, 2026

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?Sanofi and AbbVie are compared as major pharmaceutical companies with different growth drivers. Sanofi, powered by Dupixent's strong performance and newer medicines, trades at a lower valuation (7.82x forward earnings) with a 4.5% dividend yield, while AbbVie relies on Skyrizi and Rinvoq to offset Humira's decline but trades at 19.62x forward earnings with a 2.5% yield. Analysts favor Sanofi (Zacks Rank #3 Hold) over AbbVie (Rank #4 Sell) due to its attractive valuation and upgraded growth outlook.Zacks Investment Research · Oct 14, 2026

Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical OfficerMatchpoint Therapeutics appointed John O'Malley, M.D., Ph.D., as Chief Medical Officer to lead clinical development of its pipeline of first-in-class oral small molecules for autoimmune and inflammatory diseases. The appointment follows the company's recent $150M Series B financing. Dr. O'Malley brings extensive immunology expertise from previous roles at CRISPR Therapeutics and Sanofi.GlobeNewswire Inc. · Oct 14, 2026

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.The Motley Fool · Oct 13, 2026

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in SchizophreniaTeva Pharmaceutical Industries announced FDA approval of Weltruza (olanzapine) extended-release injectable suspension, the first once-monthly subcutaneous formulation for treating schizophrenia in adults. The drug will launch in the U.S. in coming weeks with three dosage strengths and requires no loading doses or post-injection monitoring. This approval expands Teva's schizophrenia portfolio alongside its existing Uzedy product, which generated $140 million in sales in the first half of 2026.Zacks Investment Research · Oct 12, 2026

Retension Pharmaceuticals Announces Pricing of Initial Public OfferingRetension Pharmaceuticals, a clinical-stage biopharmaceutical company developing treatments for hypertension and cardiovascular diseases, priced its IPO at $12 per share, raising $45 million gross proceeds. The company plans to use the funds to complete Phase 2b trials and prepare for Phase 3 trials of its lead candidate RTN-001. Trading on Nasdaq under ticker RTSN is expected to begin October 9, 2026.GlobeNewswire Inc. · Oct 9, 2026

Press Release : Availability of the aide-mémoire for Q3 2026 resultsSanofi announced the availability of its Q3 2026 results aide-mémoire on October 6, 2026, with full results to be published on October 30, 2026. The company also announced expansions of strategic partnerships with Regeneron for next-generation immunology antibodies and with Cheplapharm for mature medicines.GlobeNewswire Inc. · Oct 6, 2026

Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire »Sanofi announced the publication of its Q3 2026 aide-mémoire on October 6, 2026, with full quarterly results to follow on October 30, 2026. The company also announced expansions of strategic alliances with Regeneron for next-generation immunology antibodies and with Cheplapharm for mature medicines partnerships.GlobeNewswire Inc. · Oct 6, 2026

Sanofi, Regeneron Expand Immunology Alliance With New AntibodiesSanofi and Regeneron have expanded their longstanding alliance to co-develop four next-generation long-acting antibodies targeting type II inflammation. Regeneron will receive $1 billion upfront and up to $7 billion in milestone payments, with both companies equally sharing development costs and future profits. The collaboration builds on their successful Dupixent partnership, which generated €9.3 billion in sales in H1 2026 and is projected to reach €25 billion by 2030.Zacks Investment Research · Oct 2, 2026

GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?GSK and Sanofi, two major European pharmaceutical companies, are compared across growth drivers, pipelines, and valuations. GSK shows strong specialty medicines growth (14% in H1 2026) with expanding oncology and HIV franchises, while Sanofi benefits from blockbuster Dupixent sales (up 28.6%) and stronger near-term earnings growth. Despite both holding Hold ratings, Sanofi appears better positioned due to superior earnings growth outlook, favorable valuation metrics, and positive estimate revisions, though it faces vaccine sales headwinds and heavy Dupixent reliance.Zacks Investment Research · Sep 29, 2026

SN

SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)

SNY

Pay with—

Available Balance0.00

Your PositionYou don't own any SNY yet.

Related Tickers

Earnings

Dividends

Last · May 4

Amount$2.42

Yield5.97%

Annual$2.42